Study Suggests NT-proBNP Blood Marker May Indicate Heart Disease Risk in Older Adults
Heart disease remains the leading cause of death in the United States, with someone succumbing to it every 34 seconds, according to the Centers for Disease Control and Prevention (CDC). Regular screenings to monitor heart health are vital for assessing cardiovascular risk, with the American Heart Association (AHA) highlighting key tests such as blood pressure, cholesterol, body weight, and blood glucose. A recent study published in August has found that elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP), a heart stress marker, could indicate an increased risk of heart disease among older adults.
The study involved 8,454 participants, with a mean age of 78 years, who were free of prior cardiovascular disease at the beginning of the study. Researchers measured NT-proBNP levels at the start and again after three years. The findings revealed that 10.6% of participants developed incident heart stress after three years, while 15.1% exhibited sustained heart stress, defined as having heart stress at both baseline and year three. Both groups were found to be at a higher risk for cardiovascular events and mortality. After an eight-year follow-up, the adjusted absolute risk for cardiovascular disease was reported at 16.5% for the incident heart stress group and 15.8% for the sustained heart stress group.
Cardiologist Karishma Patwa, MD, from Manhattan Cardiology, commented on the study, noting that it suggests cardiovascular risk is dynamic. However, she emphasized that the study does not establish that lowering NT-proBNP levels directly reduces cardiovascular risk and mortality, indicating that it should be regarded as a promising prognostic finding rather than a definitive treatment target.
Kaustubh Dabhadkar, MD, MPH, FACC, a preventive cardiologist at Novant Health, added that while NT-proBNP is a useful indicator, it is just one of many factors in diagnosing heart failure. He cautioned that elevated NT-proBNP levels could arise from various conditions, including aging and kidney disease, and should be interpreted in conjunction with other clinical assessments.
The study's demographic limitations were also noted, as 98% of participants were white, raising questions about the applicability of NT-proBNP testing across diverse populations. Furthermore, experts highlighted the potential for unnecessary anxiety among patients who may misinterpret elevated NT-proBNP levels without any clinical signs of heart failure.
Despite the promising nature of these findings, both experts agreed that more evidence is needed before NT-proBNP can be recommended for routine cardiovascular risk assessment. They emphasized the importance of considering clinical context, including symptoms and other potential causes of elevated NT-proBNP levels, before making any clinical decisions. Further evaluations may involve additional tests such as ECGs and echocardiograms to assess heart function accurately.
In conclusion, while the study presents intriguing insights into the potential role of NT-proBNP in identifying heart disease risk in older adults, caution is warranted in its application until further research can substantiate its effectiveness in routine screenings.




